EGFR Biomarkers

Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.

The drug firm expects to begin a Phase I/II tumor-agnostic trial of the drug in genetically defined cancers in the second half of 2021.

The company submitted data from the ADAURA study, and the agency is slated to issue a decision on the application by the first quarter in 2021.

A pooled analysis of clinical trials and real-world data shows that the anti-tumor activity of Boehringer Ingelheim's TKI is unaffected by patients' ethnicity.

The MET inhibitor OMO-1 will be studied with Allist's EGFR inhibitor furmonertinib in patients with MET-positive, EGFR-mutated cancers.

NICE is reversing its earlier negative recommendation for the lung cancer drug after AstraZeneca agreed to provide it at a discount.

The final GioTag data suggests a survival benefit with the regimen among patients with EGFR-mutant NSCLC harboring acquired T790M resistance mutations.

Outcomes from the US cohort of the GioTag study confirm the benefit of Tagrisso for NSCLC patients who have become resistant to first-line Gilotrif.